School governing bodies and parents will no longer be able to prevent pupils from getting condoms at schools, according to a new basic education department policy released on Wednesday.
- Published
- 14 June 2017
- From
-
Bhekisisa
Women taking various forms of hormonal contraceptives can likely combine them safely with antiretrovirals (ARVs), whether as HIV treatment or in the form of Truvada (tenofovir disoproxil fumarate/emtricitabine) as pre-exposure prophylaxis (PrEP) against the virus. The one ARV that may be problematic to combine with such forms of birth control is Sustiva (efavirenz), which is included in Atripla (efavirenz/tenofovir disoproxil fumarate/emtricitabine).
- Published
- 30 May 2017
- From
-
Poz
The World Health Organization's reclassification last month of progestogen-only injectable contraceptives has triggered a critical debate in the family planning community over how to manage the potential link between higher rates of HIV acquisition and one of the most popular birth control methods in many at-risk communities.
- Published
- 04 April 2017
- From
-
Devex
Injectable progestogens are the most widely used contraceptives in sub-Saharan Africa, including in countries with high HIV prevalence. On 2 March 2017, the World Health Organisation (WHO) released revised guidance on the use of hormonal contraceptives by women at high risk of HIV infection.
- Published
- 06 March 2017
- From
-
Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study
The World Health Organization (WHO) convened a technical consultation during 1–2 December 2016 to review new evidence on the risk of HIV acquisition with the use of hormonal contraception. The issue was recognized as a critical one, particularly for sub-Saharan Africa, where women have a high lifetime risk of acquiring HIV, hormonal contraceptives constitute a significant component of the contraceptive method mix and unintended pregnancy is a common threat to the well-being and lives of women and girls.
- Published
- 03 March 2017
- From
-
WHO
The antiretroviral (ARV)-containing vaginal ring form of pre-exposure prophylaxis (PrEP) that reduced HIV risk in a major trial does not lower the effectiveness of hormonal birth control. This finding assuages concerns raised by previous research that the non-nucleoside reverse transcriptase inhibitor (NNRTI) class of ARVs has been associated with a lowered effectiveness of some hormonal contraceptives.
- Published
- 16 February 2017
- From
- Poz
On January 23, President Donald Trump reinstated the Mexico City Policy via presidential memorandum. The policy requires foreign non-governmental organizations (NGOs) to certify that they will not “perform or actively promote abortion as a method of family planning,” using funds from any source (including non-U.S. funds), as a condition for receiving U.S. government global family planning assistance and, as of Jan. 23, 2017, any other U.S. global health assistance.
- Published
- 24 January 2017
- From
-
Kaiser Family Foundation
The president has reinstated a contentious policy that blocks funding to international family-planning organizations unless they agree not to promote abortion.
- Published
- 23 January 2017
- From
-
The Atlantic
The World Health Organization will convene an expert review group later in 2016 to examine the links between the use of various hormonal contraceptive methods and women’s risk of HIV acquisition. The expert review group will assess whether current WHO guidance needs to change in the light of a new review of data, published in AIDS on 9 August 2016, which was commissioned by WHO.
- Published
- 15 August 2016
- From
- World Health Organization
Women in sub-Saharan Africa who use modern contraceptives are more likely to be tested for HIV than those who do not, according to a study published April 25, 2016 in the open-access journal PLOS ONE by Katherine Center from the University of Arizona and colleagues.
- Published
- 27 April 2016
- From
-
Eurekalert Inf Dis
Antiretroviral drug chartA one-page reference guide to the anti-HIV drugs licensed for use in the UK or European Union, with information on formulation, dosing, key side effects and food requirements.
Your next stepsA booklet with information for people who’ve just found
out they have HIV.
Coming soon: news from IAS 2019 05 July 2019The 10th International AIDS Society
conference (IAS 2019) is being held...
Those who are not seen are not heard 01 July 2019A commentary on Optimising the Impact of Key Population Programming...
The fight for access to abortion care in Europe 27 June 2019Access to
sexual and reproductive health and rights includes safe and...